.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Argus Health
Healthtrust
Cerilliant
Farmers Insurance
Cantor Fitzgerald
Daiichi Sankyo
US Department of Justice
US Army
Harvard Business School

Generated: November 17, 2017

DrugPatentWatch Database Preview

Aspirin - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for aspirin and what is the scope of aspirin freedom to operate?

Aspirin
is the generic ingredient in fifty-three branded drugs marketed by Bayer, New Haven Pharms, Plx Pharma, Savage Labs, Actavis Elizabeth, Watson Labs, Allergan Sales Llc, Ivax Pharms, Halsey, Puracap Pharm, Nostrum Labs Inc, Hikma Intl Pharms, Quantum Pharmics, Lannett, PII, Sandoz, Nexgen Pharma Inc, Mayne Pharma Inc, Stevens J, Vintage Pharms Llc, Sun Pharm Inds, Medicis, Prinston Inc, Teva, Alra, Ivax Sub Teva Pharms, Xanodyne Pharm, Novast Labs Ltd, Oxford Pharms, Meda Pharms, Heritage Pharms Inc, Ingenus Pharms Nj, Barr, Sandoz Inc, Par Pharm Inc, Zydus Pharms Usa Inc, Impax Labs Inc, Boehringer Ingelheim, Amneal Pharms, Schwarz Pharma, Abbott, Caraco, Par Pharm, Medpointe Pharm Hlc, Robins Ah, Mcneil, Aralez Pharms, Endo Pharms, Actavis Labs Fl Inc, Roxane, Sanofi Aventis Us, Bristol Myers Squibb, and Aaipharma Llc, and is included in eighty-one NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aspirin has thirty-two patent family members in eighteen countries and two supplementary protection certificates in two countries.

There are twenty-one drug master file entries for aspirin. One supplier is listed for this compound.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Stevens J
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
aspirin; caffeine; orphenadrine citrate
TABLET;ORAL074988-002Apr 30, 1999DISCNNoNo► Subscribe► Subscribe► Subscribe
Endo Pharms
PERCODAN
aspirin; oxycodone hydrochloride
TABLET;ORAL007337-007Aug 5, 2005AARXYesYes► Subscribe► Subscribe► Subscribe
Sandoz
PROPOXYPHENE COMPOUND 65
aspirin; caffeine; propoxyphene hydrochloride
CAPSULE;ORAL080044-002Sep 16, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Sandoz
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE
aspirin; caffeine; orphenadrine citrate
TABLET;ORAL074654-002Dec 31, 1996RXNoYes► Subscribe► Subscribe► Subscribe
Zydus Pharms Usa Inc
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206753-001Aug 29, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Stevens J
METHOCARBAMOL AND ASPIRIN
aspirin; methocarbamol
TABLET;ORAL081145-001Jan 31, 1995RXNoYes► Subscribe► Subscribe► Subscribe
Amneal Pharms
ASPIRIN AND DIPYRIDAMOLE
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL206392-001Mar 8, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
AGGRENOX
aspirin; dipyridamole
CAPSULE, EXTENDED RELEASE;ORAL020884-001Nov 22, 1999ABRXYesYes► Subscribe► Subscribe ► Subscribe
Mayne Pharma Inc
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE
aspirin; butalbital; caffeine; codeine phosphate
CAPSULE;ORAL203335-001Oct 30, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Nexgen Pharma Inc
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
aspirin; butalbital; caffeine; codeine phosphate
CAPSULE;ORAL075231-001Nov 30, 2001ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: aspirin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,730,884pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same► Subscribe
8,911,752Methods of making compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity► Subscribe
9,687,551Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: aspirin

Country Document Number Estimated Expiration
China1543358► Subscribe
World Intellectual Property Organization (WIPO)2013049749► Subscribe
Japan2010031044► Subscribe
China103957888► Subscribe
Canada2431606► Subscribe
MexicoPA03005550► Subscribe
Austria414542► Subscribe
Hong Kong1200098► Subscribe
Cyprus1110474► Subscribe
Mexico2014003890► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ASPIRIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
12/048Ireland► SubscribePRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
2012000017Germany► SubscribePRODUCT NAME: ASPIRIN UND ESOMEPRAZOL - MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 81047.00.00 20110930 FIRST REGISTRATION: PORTUGAL 5402359 5402367 5402375 20110812
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
UBS
Fish and Richardson
Dow
Citi
Moodys
Baxter
Fuji
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot